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ABSTRACT
Purpose: We aimed to study the potential influence of tumour blood flow –
obtained from dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)- 
in the metabolomic profiles of endometrial tumours.
Methods: Liquid chromatography coupled to mass spectrometry established the 
metabolomic profile of endometrial cancer lesions exhibiting high (n=12) or low 
(n=14) tumour blood flow at DCE-MRI. Univariate and multivariate statistics (ortho-
PLS-DA, a random forest (RF) classifier and hierarchical clustering) and receiver 
operating characteristic (ROC) curves were used to establish a panel for potentially 
discriminating tumours with high versus low blood flow.
Results: Tumour blood flow is associated with specific metabolomic signatures. 
Ortho-PLS-DA and RF classifier resulted in well-defined clusters with an out-of-bag 
error lower than 8%. We found 28 statistically significant molecules (False Discovery 
Rate corrected p<0.05). Based on exact mass, retention time and isotopic distribution 
we identified 9 molecules including resolvin D and specific lysophospholipids 
associated with blood flow, and hence with a potentially regulatory role relevant in 
endometrial cancer.
Conclusions: Tumour flow parameters at DCE-MRI quantifying vascular tumour 
characteristics are reflected in corresponding metabolomics signatures and highlight 
disease mechanisms that may be targetable by novel therapies.
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INTRODUCTION
Endometrial cancer (EC) is the most common 
gynaecologic malignancy in the high-income countries, 
and its incidence has increased by 21% since 2008 [1]. 
Presently, the treatment and prognosis are influenced by 
a subset of parameters based on molecular markers and 
the microscopic appearance of the tumours. Although 
approximately 75% of patients are primary curable by 
surgery and adjuvant treatment, 15-20% of these tumours 
will recur, with an aggressive and therapy-resistant 
behavior [2]. Several events (including genetic alterations 
and tumour microenvironment factors) have been reported 
to be activated or co-existing in aggressive endometrial 
cancer [3].
Angiogenesis is an essential mechanism for 
tumour growth, invasion and metastatic spread in 
many cancers types [4]. Moreover, tumour-associated 
vessels are frequently structurally and functionally 
abnormal, exhibiting delayed maturation and increased 
permeability [5].
In EC, increased microvascular proliferation correlates 
with a more aggressive phenotype [6-8]. Furthermore, high 
microvascular proliferation is associated with lower tumour 
blood flow (Fb) based on dynamic contrast-enhanced 
magnetic resonance imaging (DCE-MRI), and low tumour 
Fb is observed in EC patients with reduced recurrence /
progression-free survival [6, 9]. Altogether, is consistent 
with the hypothesis that vascular proliferation with coexisting 
disorganized angiogenesis promotes tumour progression and 
metastatic spread in EC [6].
Cancer was primarily considered a proliferative 
disorder; however, altered cell metabolism has emerged 
as a “hallmark of cancer”, since growing tumour cells 
rewire their metabolic program to meet the biosynthetic 
and bioenergetic demands of constant cell growth and 
phenotype changes. Metabolomics analysis provides direct 
evidences of biochemical context-dependent changes that 
can be correlated with the pathologic state of a cell, tissue 
or organ [10]. Therefore, metabolomics has been applied 
to reveal new mechanisms in cancer development and has 
identified specific biomarkers relevant for diagnosis and 
prognosis in various cancers.
The present study explores the different 
metabolomic tumour signatures potentially characterizing 
EC lesions exhibiting high versus low tumour blood 
flow at DCE-MRI. The identification of high versus 
low Fb metabolic biomarkers may highlight preoperative 
functional tumour characteristics with potential relevance 
for preoperative risk assessment and for identification of 
EC patients with expected poor outcome.
RESULTS
The main objective of this work was to determine 
metabolomics differences based on tumour Fb using a 
non-targeted metabolomics approach. We employed 
multivariate statistics to study changes in whole sample 
metabolome both in unsupervised-principal component 
(PCA) and hierarchical clustering analysis- and in 
supervised approaches-partial least discriminate analysis 
(PLS-DA), ortho-PLS-DA and Random Forest (RF) [11].
Patients had a mean age of 68 years and 20/26 
(77%) of tumours had endometrioid histology (Table 
1). In total 17/26 (66%) were classified as early stage 
(FIGO 1: Federation International of Gynecology 
and Obstetrics), and received no adjuvant therapy in 
accordance with national guidelines. 4/6 (67%) of non 
endometrioid histological subtype patients received 
adjuvant chemotherapy.
In the present work PCA analysis was chosen as an 
unsupervised method (Figure 1). This analysis showed that 
lesions with high tumour Fb clustered better than lesions 
exhibiting low tumour blood flow. Once we discarded the 
presence of outliers and checked the technical quality of 
the technique we applied ortho-PLSDA as a specific tool 
for clustering (Figure 2A). This analysis resulted in two 
well-defined clusters (Q2=0.656 and R2Y =0.985). RF 
analysis reinforced these results showing an out of bag 
error of 0.07 (Figure 2B). Because of endometrioid and 
non-endometrioid tumours are different EC subtypes we 
also performed statistics excluding non-endometrioid EC 
patients obtaining similar results (Supplementary Figure 
1A-1C). Specifically multivariate statistics show a good 
culsterization according to high and low tumour Fb (ortho-
PLSDA parameters: Q2 =0.553 and R2Y =0.979, random 
forest out of bag error = 0.1).
The analysis revealed 28 statistically significant 
molecules (Table 2). The annotation process (using 
exact mass, retention time and isotopic distribution) 
disclosed several lipids belonging to phospholipid, 
glycerolypid and sphinogolipid families. Specifically, 
four lysophosphatidylcholines were up-regulated 
in tumours with high Fb. Moreover, resolvin D was 
identified as a potential tumour Fb biomarker. The 
ROC curve of resolvin D (AUC= 0.855, specificity= 
0.9 and sensitivity = 0.7) confirmed the robustness of 
this metabolite to predict high tumour Fb (Figure 3A). 
To further study the predictive value of the metabolites 
found, we applied ROC curves using groups of 
metabolites (5, 10, 15, 25, 50 and 100) with lowest 
p-value obtained from T-Test between EC tumours 
with high versus low Fb observing a higher sensitivity 
and specificity when only the statistical significant 
metabolites (T-Test, Benjamini Hochberg False 
Discovery Rate, p<0.05) with a potential identity were 
used (Supplementary Figure 2). Using these metabolites 
we could reach a higher predictive value than using 
only Resolvin D1. Finally, we applied hierarchical 
clustering analyses using the 25 most statistically 
significant metabolites and an almost perfect separation 
between groups was observed (Figure 3B).
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DISCUSSION
Advanced DCE-MRI techniques enable 
visualization and quantification of functional tumour 
characteristics in vivo. Previous studies revealed that in 
EC, low tumour Fb accompanied by increased capillary 
leakage and high microvascular proliferation is associated 
with reduced recurrence/progression free survival [6, 9]. 
These associations are somewhat puzzling, but may be 
related to the fact that tumoural angiogenesis generates 
vessels that in spite of being abundant, are heterogenous 
and rough making them altogether dysfunctional [12]. 
Further, the negative impact of low tumour Fb and 
disorganized angiogenesis have suggested tumour hypoxia 
promotes tumour progression and metastatic spread in 
endometrial carcinomas [13].
Based on these premises we designed an experiment 
to evaluate potential changes in tissue metabolome 
according to whether the tumours preoperatively exhibited 
high- or low Fb.
Previous studies have suggested a specific 
metabolomics signature of EC compared to normal 
tissue [14], but the present results indicate that there is a 
specific metabolome associated with tumour Fb, suggesting 
important changes in tumour metabolism which could 
modulate EC progression and angiogenesis related 
resistance to treatment [15]. Among all statistically different 
molecules found, we detected lipid species belonging to 
different families including phospholipids and, specifically, 
lysophospholipids (LPL). LPL were first discovered as 
constituents of cell membranes; however, today we know 
that they can also act as signalling molecules, playing 
important roles in central processes in cancer: stimulating 
angiogenesis, inhibiting apoptosis or modulating immune 
response [16]. In our study we identified several LPL 
species increased in high Fb EC patient tissues. Specifically, 
in this work we describe, for the first time, the potential role 
of lysophophatydilcholine (18:1), lysophosphatydilserine 
(14:0), lysophosphatydilinositol (20:0) and 
lysophosphatydilcholine (20:3) in EC tumour progression. 
These results reinforce the idea of LPL metabolism as 
a disease modifier in EC progression. Furthermore, this 
study has revealed that tissue resolvin D could be a good 
predictor of high tumour Fb (generally correlated to better 
patient survival). Resolvin D is known to be involved in 
the resolution of inflammation processes and shows potent 
effects in protecting against neovascularization and hypoxia 
in some pathological diseases [17]. Thus, our findings 
Table 1: Clinicopathological patient characteristics (n = 26) of women treated for endometrial cancer and evaluated 
by enhanced contrast MRI and metabolomics
Age; mean (range) years 68 (41-93)
Postmenopausal, n (%) 23 (89)
Lymph node sampling performed, n (%) 21 (81)
Adjuvant therapy received, n (%) 9 (35)
FIGO stagea, n (%)
 IA 10 (39)
 IB 7 (27)
 II 4 (15)
 III 4 (15)
 IV 1 (4)
Histologic differentiation, n (%)
 Grade 1 5 (19)
 Grade 2 5 (19)
 Grade 3 16 (62)
Histologic subtype, n (%)
 Endometrioid 20 (77)
 Clear cell 1 (4)
 Serous 3 (11)
 Carcinosarcoma 2 (8)
aAccording to International Federation of Gynaecology and Obstetrics (FIGO) 2009 staging criteria (ref)
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Figure 1: PCA demonstrate a metabolomic-specific signature depending on tumour blood flow in endometrial cancer 
patients. Red spots represent high tumour blood flow and green spots represent low tumour blood flow as determined by DCE-MRI.
Figure 2: (A) Ortho-PLSDA algorithm using all metabolites found in samples from endometrial cancer tumours is able to discriminate 
groups with an observed Q2 of 0. 656 and observed R2Y of 0.985. Red spots represent high tumour blood flow patients and green spots 
represent low tumour blood flow as determined by DCE- MRI. (B) RF classification shows and overall classification error of 0.07.
Oncotarget109022www.impactjournals.com/oncotarget
suggest that loss of the protective and inflammatory-
resolution effect induced by tumour LPL and Resolvin D 
coexists with vascular proliferation leading to disorganized 
angiogenesis and hypoxia, relevant mechanisms in tumour 
progression and metastatic spread in EC [13].
All in all, the present work delves into the different 
signalling molecules involved in tumour progression. 
These achievements can serve to better understand EC 
metabolism helping to develop, in a near future, novel and 
more personalized therapies. Moreover, our results support 
the promising role of DCE-MRI as preoperative non-
invasive imaging tool depicting tumour vascular features 
relevant for the corresponding metabolomic tumour 
signature that may be targetable in EC therapy.
Table 2: Metabolites from endometrial cancersignificantly different expressed in tumors with high versus low blood 
flow (Fb) determined by dynamic contrast enhanced (DCE)-MRI blood flow (Student’s T-Test, p<0.05)
Potential ID (exact mass) p (Corr) Regulation (H vs L) FC Mass Retention Time
Unknown 0.001717 down -3140.98 645.2509 12.776092
Unknown 0.002955 down -1.55451 529.339 10.614731
Unknown 0.002955 down -2.36942 640.2945 12.776231
LysoPS(14:0) 0.002955 up 1313.153 469.2301 11.289364
Unknown 0.002955 up 2939.315 644.3455 12.713154
MG(20:3) 0.005209 up 2786.49 380.2894 11.154073
LysoPI(20:0) 0.00663 up 451.2966 628.3694 12.711375
LysoPC(18:1) 0.0079 up 7360.114 521.3482 11.1267
Unknown 0.0079 up 744.7858 675.3582 12.709785
Unknown 0.0079 up 784.6694 380.7346 13.018824
Unknown 0.008335 up 3.061549 588.4521 12.71631
Unknown 0.008335 up 1489.749 395.3035 10.927358
Unknown 0.009024 up 4.129054 530.4012 12.716731
Unknown 0.010229 up 584.1685 294.2502 11.812234
Unknown 0.017847 down -1.76119 497.3935 5.910731
LysoPC(20:3) 0.027094 up 1097.7 545.3473 10.9397335
Unknown 0.029734 down -1.53841 185.2144 4.237846
Resolvin D 0.03647 up 480.5512 376.2332 10.606182
Unknown 0.03647 down -135.16 639.5252 12.372849
PC(42:2) 0.03647 down -251.465 869.6867 13.405749
Unknown 0.03647 down -175.365 915.7157 13.490999
Unknown 0.03647 up 319.0776 563.4208 12.652739
Unknown 0.03647 up 275.0069 344.2021 12.714
Unknown 0.03647 down -297.762 890.7981 14.891124
NeuAcalpha2-3Galbeta-
Cer(d34:1) 0.03647 up 274.8682 990.6635 10.921999
Unknown 0.03647 up 383.5934 410.2134 11.286181
Unknown 0.04131 up 861.9869 901.5447 13.720384
PI-Cer(t46:0(2OH)) 0.044655 up 223.0672 981.7524 12.743363
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Figure 4: Axial oblique T2-weighted MRI (left panel), contrast-enhanced T1-weighted MRI (middle panel) and parametric 
blood flow (Fb, right panel) map from a 68 year-old patient with FIGO stage 1B, grade 3 and high tumour Fb (upper panel) 
and a 52 year-old patient with FIGO stage 1B, grade 1 and low tumour Fb (lower panel). At conventional diagnostic MRI the 
endometrial carcinomas (arrows) are typically depicted as hyper-intense relative to the surrounding myometrium on T2-weigthed image 
while hypo-intense on contrast-enhanced T1-weighed image. On the corresponding parametric maps high blood flow is depicted as white/
red while low blood flow is depicted as dark blue.
Figure 3: (A) ROC curve of tumour resolvin D levels. (B) Hierarchical clustering analyses using 25 most statistical significant metabolites 
significantly different between endometrial cancer tumours with high versus low blood flow (Student’s T-Test, Benjamini Hochberg False 
Discovery Rate, p<0.05). Unknown identities are represented as exact mass@retention time.
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MATERIALS AND METHODS
Patients and tissue samples
Endometrial tissue from hysterectomy specimens 
was collected from 26 patients surgically treated for 
endometrial carcinoma. All patients were diagnosed 
and treated at the same university hospital (Haukeland 
University Hospital, Bergen, Norway) written informed 
consent was obtained from all patients for the collection 
of imaging data and specimens for biomarker studies 
included in an institutional review board-approved 
protocol (Rek Vest 2009/2315).
Dynamic contrast enhanced (DCE)-MRI 
protocol and blood flow (Fb) analysis
Preoperative pelvic magnetic resonance imaging 
(MRI) was performed in all patients on a 1.5 Tesla 
MRI scanner (Siemens Avanto running Syngo v. 
B17, Germany) using a six-channel body coil and a 
standardized imaging protocol [6, 9] 20 mg butyl-
scopolamine bromide (Buscopan; Boehringer, 
Germany) was administered intravenously prior to 
scanning in order to reduce motion artefacts. Contrast 
agent was administrated intravenously (Dotarem, 
Guerbet: 0.1 mmol gadolinium/kg, 3 ml/s injection 
speed). Pelvic sagittal and axial oblique (perpendicular 
to the long axis of the uterus) T2-weighted images 
were acquired together with axial oblique T1-
weighted gradient-echo images prior to contrast agent 
administration. Pelvic DCE-MRI was obtained for 12 
axial oblique slices applying a 3D spoiled gradient echo 
(FLASH) sequence (echo time/repetition time (TE/
TR) = 1.05/2.64 ms, flip angle (FA) = 12°, matrix = 
256x256, field of view (FOV) = 300 x 300 mm2, slice 
thickness = 5 mm, number of averages (NA) = 1). The 
temporal resolution was 2.49 s. and sequential images 
were acquired from 30 s before i.v. administration of 
contrast medium to 6.3 min after contrast injection. At 
2 min post contrast medium administration, a pause of 
33 s was utilized to acquire axial oblique T1-weighted 
gradient-echo contrast-enhanced images.
Regions of interests (ROIs) were drawn within the 
endometrial tumour by a radiologist (ISH with > 7 years of 
experience with pelvic MRI) who was blinded for tumour 
stage, histological diagnosis and patient outcome. Care 
was taken to avoid including necrotic and haemorrhagic 
areas of the tumours in the ROIs. The dynamic image 
series were analysed using an in-house implementation 
of the adiabatic approximation model of Johnson and 
Wilson [18]. Representative diagnostic MRI images 
and parametric DCE-MRI maps illustrating endometrial 
tumours with high and low blood flow (Fb) are shown in 
Figure 4.
Metabolomic analyses
Tissue samples (50–70 mg) were homogenized using 
20 volumes of cold methanol as previously described [14]. 
Metabolite extracts were subjected to mass spectrometry 
using an HPLC 1290 series coupled to an ESI-Q-TOF 
MS/MS 6520 (Agilent Technologies, Santa Clara, CA, 
USA) as previously described [14]. Multivariate statistic 
analyses were performed using Metaboanalyst platform 
[19]. The preliminary identification of differential 
metabolites (Student’s T-Test, Benjamini Hochberg False 
Discovery Rate, p<0.05) was performed using the PCDL 
database from Agilent (Agilent Technologies, Barcelona, 
Spain), which accounts retention times in a standardized 
chromatographic system, exact mass and isotope 
distribution as an orthogonal searchable parameters 
to complement accurate mass data (AMRT approach) 
according to previously published works [14]. The 
version of the PCDL database used had retention times 
and accurate mass data for 679 compounds. To complete 
the identification process we searched for unidentified 
metabolites in Metlin Database (https://metlin.scripps.edu/
index.php) which includes accurate masses and MS/MS 
spectrum for 961.829 molecules.
Ethical approval
All procedures performed in studies involving 
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